Document Detail

High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy.
MedLine Citation:
PMID:  9395376     Owner:  NLM     Status:  MEDLINE    
To gain insight into the long-term effect of interferon-alpha (IFN-alpha) therapy on hepatitis C virus (HCV) RNA-positive hemodialysis patients, 23 subjects were given 3 MU of IFN-alpha 3 times a week for 6 (n = 12) or 12 months (n = 11). They were followed for 19 months after cessation of therapy. Sustained serum HCV RNA clearance occurred in 42% of patients treated for 6 months and in 64% of those treated for 12 months. HCV was eradicated from 6 of 13 patients infected with HCV genotype 1b and from 2 of 6 patients also infected with hepatitis G virus. HCV RNA remained undetectable in both serum and a liver biopsy of 2 patients who were given cadaveric kidney transplants after IFN-alpha treatment. These data suggest that HCV RNA-positive dialysis patients can be considered for treatment while receiving dialysis, particularly those awaiting transplant.
J Izopet; L Rostaing; F Moussion; L Alric; M Dubois; H T That; J L Payen; M Duffaut; D Durand; J M Suc; J Puel
Related Documents :
21398606 - Memory ccr6+cd4+ t cells are preferential targets for productive hiv type 1 infection r...
15853986 - Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis...
16518956 - Hepatic interferon receptor mrna expression: clinical relevance and its relationship wi...
17106926 - Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhi...
9024986 - Cd8+ cells in hiv infection produce macrophage inflammatory protein-1 alpha and rantes:...
2473046 - Replication of hiv in human fetal retinal cultures and established pigment epithelial c...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  176     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1998-01-15     Completed Date:  1998-01-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1614-7     Citation Subset:  AIM; IM    
Laboratoire de Virologie, and Service de Médecine Interne, Hôpital Purpan, Centre Hospitalier Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  therapeutic use*
Flaviviridae / genetics,  isolation & purification
Hepacivirus / genetics,  isolation & purification*
Hepatitis C Antibodies / analysis
Hepatitis C, Chronic / drug therapy*,  virology
Hepatitis, Viral, Human / complications,  diagnosis
Interferon Alfa-2b / administration & dosage,  therapeutic use*
Kidney Transplantation / adverse effects
Liver / virology
Middle Aged
Pilot Projects
RNA, Viral / analysis,  blood
Renal Dialysis*
Transaminases / metabolism
Reg. No./Substance:
0/Antiviral Agents; 0/Hepatitis C Antibodies; 0/RNA, Viral; 99210-65-8/Interferon Alfa-2b; EC 2.6.1.-/Transaminases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatitis A virus infections in urban children--are preventive opportunities being missed?
Next Document:  Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK...